SCHEMBL20161634

SCHEMBL20161634

Cn1c(=O)c2c(ncn2CC(=O)NCc2ccc(Cl)c(Cl)c2)n(C)c1=O

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
HTT P42858 1/20 0.68
UBE2N P61088 1/20 0.68
GAA P10253 1/20 0.66
KMT2A Q03164 2/20 0.65
MAPK1 P28482 3/20 0.65
POLB P06746 1/20 0.62
THRB P10828 1/20 0.60
RXFP1 Q9HBX9 5/20 0.60
TP53 P04637 2/20 0.60
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 1/20 0.59
MEN1 O00255 1/20 0.57
TRPA1 O75762 1/20 0.56
MAPT P10636 1/20 0.56
ADORA2B P29275 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064795 0.90 CYP1A2 (0.73) LMNASMN1; SMN2HTTUBE2NGAA
SCHEMBL10114153 0.87 LMNA (0.71) LMNASMN1; SMN2HTTUBE2NGAA
SCHEMBL12584223 0.85 LMNA (0.71) LMNASMN1; SMN2GAAKMT2AMAPK1
SCHEMBL10113976 0.84 LMNA (0.70) LMNASMN1; SMN2GAAKMT2AMAPK1
SCHEMBL10114298 0.84 CYP1A2 (0.82) LMNASMN1; SMN2HTTGAAKMT2A
SCHEMBL19036657 0.84 LMNA (0.47) LMNASMN1; SMN2HTTUBE2NGAA
SCHEMBL10113992 0.84 LMNA (0.79) LMNASMN1; SMN2GAAKMT2AMAPK1
SCHEMBL12584285 0.84 GAA (0.72) LMNAGAAKMT2AMAPK1THRB
SCHEMBL10113892 0.83 RXFP1 (0.76) LMNASMN1; SMN2HTTUBE2NGAA
SCHEMBL10114496 0.82 MAPT (0.71) LMNASMN1; SMN2HTTGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 LMNA 819/4885SMN1; SMN2 129/4885HTT 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.